Greenwood Capital Associates LLC Decreases Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Greenwood Capital Associates LLC reduced its holdings in Teva Pharmaceutical Industries by 16.6%, now owning 314,305 shares worth approximately $5.27 million after selling 62,726 shares in the second quarter.
• Teva's earnings for the recent quarter showed a profit of $0.66 EPS, surpassing analyst expectations, although revenues of $4.18 billion fell short of the forecasted $4.34 billion.
• Recent analyst ratings for Teva have turned positive, with UBS raising its target price from $23.00 to $26.00 and a consensus rating of "Buy" among multiple analysts.

Greenwood Capital Associates LLC decreased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 16.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 314,305 shares of the company's stock after selling 62,726 shares during the quarter. Greenwood Capital Associates LLC's holdings in Teva Pharmaceutical Industries were worth $5,268,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. US Bancorp DE boosted its stake in shares of Teva Pharmaceutical Industries by 6.5% during the 1st quarter. US Bancorp DE now owns 10,812 shares of the company's stock valued at $166,000 after purchasing an additional 656 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 15.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,474 shares of the company's stock valued at $92,000 after purchasing an additional 715 shares in the last quarter. Bfsg LLC boosted its stake in shares of Teva Pharmaceutical Industries by 7.8% during the 1st quarter. Bfsg LLC now owns 10,960 shares of the company's stock valued at $168,000 after purchasing an additional 790 shares in the last quarter. Factorial Partners LLC boosted its stake in shares of Teva Pharmaceutical Industries by 0.3% during the 1st quarter. Factorial Partners LLC now owns 333,000 shares of the company's stock valued at $5,118,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Yousif Capital Management LLC boosted its stake in shares of Teva Pharmaceutical Industries by 1.9% during the 1st quarter. Yousif Capital Management LLC now owns 55,986 shares of the company's stock valued at $861,000 after purchasing an additional 1,033 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Down 0.1%

Shares of NYSE TEVA opened at $20.05 on Friday. The firm's 50 day moving average price is $18.05 and its 200-day moving average price is $16.79. The company has a market cap of $23.00 billion, a PE ratio of -125.31, a P/E/G ratio of 1.17 and a beta of 0.71. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business's revenue was up .3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 52,742 shares of the company's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Placid Jover sold 6,053 shares of the business's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the transaction, the insider directly owned 6,774 shares of the company's stock, valued at $102,693.84. The trade was a 47.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.49% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on TEVA. UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, September 24th. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 price objective on the stock. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $25.14.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.